Meeting
2022 ASCO Annual Meeting
The combination of CD16A/EGFR innate cell engager, AFM24, with SNK01 autologous natural killer cells in patients with advanced solid tumors.
Authors
Anthony B. El-Khoueiry
University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA
Anthony B. El-Khoueiry , Paul Y. Song , Jennifer Rubel , Dorna Y. Pourang , Christa Raab , Gabriele Hintzen , Michael Emig , Pilar Nava-Parada
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Antibodies
Clinical Trial Registration Number
NCT05099549
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS2675)
DOI
10.1200/JCO.2022.40.16_suppl.TPS2675
Abstract #
TPS2675
Poster Bd #
326b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
AFM24 in combination with atezolizumab in patients with advanced EGFR-expressing solid tumors: Phase 1/2a study design and rationale.
First Author: Omar Saavedra Santa Gadea
Poster
2023 ASCO Breakthrough
AFM24 in combination with autologous NK cells (SNK01) in patients with advanced/metastatic epidermal growth factor receptor (EGFR) expressing solid tumors: Initial results from the phase 1 dose‑escalation study.
First Author: Anthony B. El-Khoueiry
Poster
2023 ASCO Annual Meeting
EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors.
First Author: Charu Aggarwal
Poster
2023 ASCO Annual Meeting
Phase Ib/IIa safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced solid tumors.
First Author: Ye Guo